Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
289.8 INR | +0.09% | +8.53% | +16.16% |
Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.16% | 4.15B | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.02% | 22.2B | |
-16.53% | 21.23B | |
-8.68% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Transcript : Biocon Limited, Q3 2014 Earnings Call, Jan 23, 2014